These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 2878742)

  • 1. Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction.
    Sato H; Inoue M; Matsuyama T; Ozaki H; Shimazu T; Takeda H; Ishida Y; Kamada T
    Circulation; 1987 Jan; 75(1):213-20. PubMed ID: 2878742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of left ventricular contractility and relaxation with the beta 1-adrenergic receptor partial agonist xamoterol at rest and during exercise in patients with postinfarction left ventricular dysfunction. A placebo-controlled randomized trial.
    de Feyter PJ; Serruys PW; Suryapranata H
    Circulation; 1990 Feb; 81(2 Suppl):III99-106. PubMed ID: 1967562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.
    Virk SJ; Davies MK
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):15S-22S. PubMed ID: 2572250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blunted cardiac responses to exercise-induced sympathetic stimulation in non-failing aortic regurgitation: insight into role of cardiac dilation in hyporesponse of failing hearts.
    Matsuyama T; Sato H; Kitabatake A; Ozaki H; Imai K; Ishida Y; Hori M; Inoue M; Kamada T
    Jpn Circ J; 1992 Feb; 56(2):117-27. PubMed ID: 1548833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hemodynamic and humoral changes following intravenous administration of xamoterol in patients with heart failure and coronary heart disease].
    Erlemeier HH; Kupper W; Bleifeld W
    Z Kardiol; 1990 Feb; 79(2):126-33. PubMed ID: 1969685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and chronic hemodynamic effects of xamoterol in mild to moderate congestive heart failure.
    Virk SJ; Qiang FX; Anfilogoff NH; Murray RG; Littler WA; Davies MK
    Am J Cardiol; 1991 May; 67(12):48C-52C; discussion 52C-54C. PubMed ID: 1673587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of xamoterol (ICI 118587), a new beta1 adrenoceptor partial agonist, on resting haemodynamic variables and exercise tolerance in patients with left ventricular dysfunction.
    Molajo AO; Bennett DH
    Br Heart J; 1985 Jul; 54(1):17-21. PubMed ID: 2861834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of xamoterol a new beta-adrenoceptor partial agonist, in patients with angina pectoris.
    Barrios L; Geboers J; Piessens JH; de Geest H
    Eur J Clin Pharmacol; 1986; 29(6):667-71. PubMed ID: 2872055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of tolerance development after long-term administration of the partial beta-adrenoceptor agonist xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Cardiology; 1990; 77(1):30-9. PubMed ID: 1972349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation of diastolic function and exercise capacity in ischemic left ventricular dysfunction. Role of beta-agonists and beta-antagonists.
    Pouleur H; Hanet C; Rousseau MF; van Eyll C
    Circulation; 1990 Aug; 82(2 Suppl):I89-96. PubMed ID: 1973644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of xamoterol in Shy-Drager syndrome.
    Obara A; Yamashita H; Onodera S; Yahara O; Honda H; Hasebe N
    Circulation; 1992 Feb; 85(2):606-11. PubMed ID: 1346511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atenolol improves ventricular function without changing plasma noradrenaline but decreasing plasma atrial natriuretic factor in chronic heart failure.
    Gabrielli O; Puyó AM; De Rosa A; Armando I; Barontini M; Levin G
    Auton Autacoid Pharmacol; 2002; 22(5-6):261-8. PubMed ID: 12866806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predominant beta-adrenoceptor blocking effect of xamoterol averaged over the day in patients with mild to moderate heart failure: insight into the mechanism of its long-term clinical efficacy.
    Ozaki H; Sato H; Hori M; Matsuyama T; Imai K; Yokoyama H; Kitabatake A; Inoue M; Kamada T
    Eur J Clin Pharmacol; 1992; 43(5):455-61. PubMed ID: 1362383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The value of xamoterol in moderate ischemic cardiac insufficiency].
    Rousseau MF; Cheron P; Vincent MF; Pouleur H; Lavenne F
    Ann Cardiol Angeiol (Paris); 1984; 33(4):215-8. PubMed ID: 6147115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exercise capacity, arrhythmias, humoral and chemical parameters during long-term therapy with xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Int J Cardiol; 1990 Aug; 28(2):197-208. PubMed ID: 1697569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Noninvasive evaluation of partial beta adrenergic agonist properties of xamoterol in cardiac insufficiency].
    Richaud M; Lechat P; Komajda M; Landault C; Fournier P; Fraysse JB; Grosgogeat Y
    Arch Mal Coeur Vaiss; 1990 Feb; 83(2):247-52. PubMed ID: 1968739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic effects of Corwin (ICI 118,587), a new cardioselective beta-adenoceptor partial agonist.
    Detry JM; Decoster PM; Brasseur LA
    Eur Heart J; 1983 Aug; 4(8):584-91. PubMed ID: 6139282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The acute effects of intravenous xamoterol ('Corwin', I.C.I. 118, 587) on resting and exercise haemodynamics in patients with mild to moderate heart failure.
    Virk SJ; Anfilogoff NH; Lawson N; Sadler AM; Smith SJ; Nuttall A; Murray RG; Littler WA; Davies MK
    Eur Heart J; 1989 Mar; 10(3):227-34. PubMed ID: 2565233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sympathetic modulation in practice: the German clinical experience.
    Kupper W; Erlemeier HH; Bleifeld W
    Eur Heart J; 1990 Apr; 11 Suppl A():19-25. PubMed ID: 1971586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol.
    Jennings G; Bobik A; Oddie C; Restall R
    Clin Pharmacol Ther; 1984 May; 35(5):594-603. PubMed ID: 6143634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.